Elranatamab
Pfizer
['elranatamab']
data from elranatamab (bcma x cd3 bispecific) in patients pretreated with anti-bcma agents from magnetismm studies. overall response rate of 46% seen, indicating ability to provide a meaningful response even in this patient population. #asco23 
Multiple Myeloma Research Foundation - Accelerating the development of next generation #myeloma treatments to extend patient’s lives, and lead to a cure.